Gataparsen

Drug Profile

Gataparsen

Alternative Names: ISIS 23722; LY-2181308; Survivin ASO

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Eli Lilly
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action BIRC5 protein inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Non-small cell lung cancer; Prostate cancer

Most Recent Events

  • 18 Apr 2012 Discontinued - Phase-II for Acute myeloid leukaemia in USA (IV)
  • 18 Apr 2012 Discontinued - Phase-II for Non-small cell lung cancer in Belgium (IV)
  • 18 Apr 2012 Discontinued - Phase-II for Non-small cell lung cancer in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top